LYNN ZECHIEDRICH to Drug Resistance, Bacterial
This is a "connection" page, showing publications LYNN ZECHIEDRICH has written about Drug Resistance, Bacterial.
Connection Strength
1.775
-
Wicked: The untold story of ciprofloxacin. PLoS Pathog. 2018 03; 14(3):e1006805.
Score: 0.477
-
Toward repurposing ciclopirox as an antibiotic against drug-resistant Acinetobacter baumannii, Escherichia coli, and Klebsiella pneumoniae. PLoS One. 2013; 8(7):e69646.
Score: 0.347
-
Novel Conserved Genotypes Correspond to Antibiotic Resistance Phenotypes of E. coli Clinical Isolates. PLoS One. 2013; 8(6):e65961.
Score: 0.345
-
Increased fluoroquinolone resistance with time in Escherichia coli from >17,000 patients at a large county hospital as a function of culture site, age, sex, and location. BMC Infect Dis. 2008 Jan 15; 8:4.
Score: 0.237
-
Contributions of the combined effects of topoisomerase mutations toward fluoroquinolone resistance in Escherichia coli. Antimicrob Agents Chemother. 2007 Nov; 51(11):4205-8.
Score: 0.229
-
Temporal interplay between efflux pumps and target mutations in development of antibiotic resistance in Escherichia coli. Antimicrob Agents Chemother. 2012 Apr; 56(4):1680-5.
Score: 0.078
-
Relationships among ciprofloxacin, gatifloxacin, levofloxacin, and norfloxacin MICs for fluoroquinolone-resistant Escherichia coli clinical isolates. Antimicrob Agents Chemother. 2009 Jan; 53(1):229-34.
Score: 0.062